Abstract:Weimin Cai, 1, &ast Xiao Wu, 1, &ast Kun Guo, 2 Yongxian Chen, 3 Yubo Shi, 4 Xinran Lin 1 1 Department of Gastroenterology and Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China; 2 Department of Cardiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China; 3 Department of Chest Cancer, Xiamen Second People's Hospital, Xiamen, 36100, People's Republic of China; 4 Department of Pulmonary, Yueqing People's Hospital, Wenzhou, 325000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xinran Lin, Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, People's Republic of China, Tel +86 18857838243, Fax +86 0576 87755312, Email Background: Accurate prediction of treatment response in Crohn's disease (CD) patients undergoing infliximab (IFX) therapy is essential for clinical decision-making. Our goal was to compare the performance of the clinical characteristics, radiomics and deep learning model from computed tomography enterography (CTE) for identifying individuals at high risk of IFX treatment failure. Methods: This retrospective study enrolled 263 CD patients from three medical centers between 2017 and 2023 patients received CTE examinations within 1 month before IFX commencement. A training cohort was recruited from center 1 (n=166), while test cohort from centers 2 and 3 (n=97). The deep learning model and radiomics were constructed based on CTE images of lesion. The clinical model was developed using clinical characteristics. Two fusion methods were used to create fusion model: the feature-based early fusion model and the decision-based late fusion model. The performances of the predictive models were evaluated. Results: The early fusion model achieved the highest area under characteristics curve (AUC) (0.85– 0.91) among all patient cohorts, significantly outperforming deep learning model (AUC=0.72– 0.82, p=0.06– 0.03, Delong test) and radiomics model (AUC=0.72– 0.78, p=0.06– 0.01). Compared to early fusion model, the AUC values for the clinical and late fusion models were 0.71– 0.91 (p=0.01– 0.41), and 0.81– 0.88 (p=0.49– 0.37) in the test and training set, respectively. Moreover, the early fusion had the lowest value of Brier's score 0.15– 0.12 in all patient set. Conclusion: The early fusion model, which integrates deep learning, radiomics, and clinical data, can be utilized to predict the response to IFX treatment in CD patients and illustrated clinical decision-making utility. Keywords: deep-learning, radiomics, Crohn's disease, infliximab, prediction Crohn's disease (CD), a main form of inflammatory bowel disease (IBD), is characterized as a chronic, remitting, and relapsing inflammatory disorder of the gastrointestinal tract, requiring ongoing management and surveillance. 1 Infliximab (IFX), shows efficacy in inducing and maintaining remission, also is the first anti-tumor necrosis factor (TNF) α agent. Yet, primary loss of response (PLR) to IFX is observed in 13–40% of CD patients, while 23–46% patients experience a secondary loss of response (SLR). 2,3 The reduction of response to IFX, an anti-TNF monoclonal antibody, is believed to result from inadequate drug levels, attributed to the antibody's degradation and clearance. Consequently, when a decrease in the IFX's effectiveness is suspected, a comprehensive assessment involving the evaluation of active inflammation, potential IBD complications, clinical symptoms, biochemical markers, endoscopic findings, and imaging should be undertaken. Furthermore, consistent monitoring of disease activity during IFX treatment is crucial, enabling timely adjustments to therapeutic strategies to achieve and maintain long-term remission. For decades, the Crohn's Disease Activity Index (CDAI) has been regarded as a valuable tool for measuring the clinical activity of CD. 4–6 Nevertheless, the accurate calculation of CDAI requires over a seven-day period and the necessity for patient compliance limits its utility in daily clinical practice. 7,8 While colonoscopy offers an objective and accurate assessment of the intestinal condition, its invasiveness, high costs, and potential risks, including perforation, bleeding, and cardiovascular complications related to sedation, detract from its desirability. 9,10 Furthermore, a considerable number of CD patients are unsuitable candidates for endoscopy due to intestinal luminal strictures or a penetrating disease phenotyp -Abstract Truncated-

A Predictive Model Based on Clinical and Computed Tomography Enterography Features to Evaluate Maintenance Efficacy of Anti-Tumor Necrosis Factor-Α Monoclonal Antibody in Crohn′s Disease Patients with Small Intestinal Involvement

Analysis on the risk factors and establishment of a prediction model for primary non-response to the treatment of anti-tumor necrosis factor-α monoclonal antibody in Crohn′s disease patients

Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn’s Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends

Efficacy predictors of a 2-month exclusive enteral nutrition for inducing remission of active Crohn’s disease

A Novel Computed Tomography Enterography Radiomics Combining Intestinal and Creeping Fat Features Could Predict Surgery Risk in Patients with Crohn’s Disease

Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn’s disease

P1020 Developing and Validating a Clinical Prediction Model Using Biomarkers to Assess Clinical Response and Severity of Crohn's Disease 12 Weeks After Initiation of Biological Therapy

Developing a Machine-Learning Prediction Model for Infliximab Response in Crohn's Disease: Integrating Clinical Characteristics and Longitudinal Laboratory Trends

Deep-Learning, Radiomics and Clinic Based Fusion Models for Predicting Response to Infliximab in Crohn's Disease Patients: A Multicentre, Retrospective Study

Su1294 Computed Tomography Enterography Versus Magnetic Resonance Enterography for Assessment of Disease Activity and Complications in Small Bowel Crohn's Disease: A Meta-Analysis of Head-to-Head Comparative Studies

P806 Development of a clinical model to predict secondary non-response of anti-TNFα treatment on Crohn's disease

Study of Spectral CT Enterography in the Evaluation of Crohn's Disease Activity by Regression Mathematical Model

Nomogram to Predict Primary Non-Response to Infliximab in Patients with Crohn's Disease: a Multicenter Study.

Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study

Identification of Targets for Subsequent Treatment of Crohn's Disease Patients after Failure of Anti-TNF Therapy.

P953 Establishment and Internal Validation of a Clinical Risk Score to Predict the Efficacy of Adalimumab in Crohn's Disease

The sensitivity and specificity of CT enterography comprehensive score in evaluating the activity of Crohn's disease

Identifying Patients with Crohn's Disease at High Risk of Primary Nonresponse to Infliximab Using a Radiomic-Clinical Model

CT-based Pancreatic Radiomics Predicts Secondary Loss of Response to Infliximab in Biologically Naïve Patients with Crohn’s Disease

Comparison of modified gunsight suture technique and traditional interrupted suture in enterostomy closure

Development of a Predictive Model to Distinguish Crohn's Disease from Other Etiologies